Etoposide

For research use only. Not for use in humans.

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Etoposide发表文献121篇:

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DUdWlEPTB;MD6xNwKBkcLz4pEJNE4xOSEQvF2= Mof0NlU6PjB{OEK=
KellyCis83 NIXRUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMUdihKnDueLCiUCuNFIh|ryP Mm\JNlU6PjB{OEK=
SK-N-AS M{PLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2THemlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= M3S2TFI2QTZyMkiy
SK-N-ASCis24 NIHmcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjNTWM2OD1yLkW35qCKyrIkgJmwMlEyKM7:TR?= NXK2NGFHOjV7NkCyPFI>
U87 M4\SSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i0clAuPTBizszN MW[0PEBp Mm\2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? MWKyOVc2ODJ5Mx?=
HCT116 M1Ladmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGwMlUuOi53IN88US=> NUX3WGdmPDkEoHlCpC=> NEHPWodKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= MofiNlU4PDZ5NkO=
HT-29 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\HO|MxNjVvMj61JO69VQ>? NGnVbXk1QMLiaNMg MoD1TWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? NVj2SG9qOjV5NE[3OlM>
Caco2 NHfz[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVywMlUuOi53IN88US=> MnrSOFjDqGkEoB?= NWS2dJhCUUN3ME23MlI3yqEEsdMgNU43QMLizszN MkLLNlU4PDZ5NkO=
COLO 205 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn0cIoxNjVvMj61JO69VQ>? NYfLTphsPDkEoHlCpC=> NFv5[WFKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= MorZNlU4PDZ5NkO=
SW480 NISwcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDZVGNkOC53LUKuOUDPxE1? NY\xem5jPDkEoHlCpC=> NEnMdYRKSzVyPUSuPVLDqMLzwrCwMlM{yqEQvF2= M4TzelI2PzR4N{[z
HEK293T NIPtU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n1WFEuPSEQvF2= MWK0POKhcMLi Mo\CTWM2OD1{LkSyxsDDucLiMD6wOeKh|ryP MoPVNlU4PDZ5NkO=
Hep3B  MoKxSpVv[3Srb36gRZN{[Xl? MmruNVAh|ryP NHzVSWg1QMLiaNMg MYny[YR2[2W|IITo[UBmdmijbnPpcoch\W[oZXP0JI9nKEKPUD22 MYeyOVY{OzV4NB?=
Hep3B  NVPqO2o3TnWwY4Tpc44hSXO|YYm= MoTHNE4yNTFyIN88US=> M3vzTVI1KGh? NY\aZplZe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B MYOyOVY{OzV4NB?=
HEK293 M133Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK0TWM2OD15LkG0xsDDucLiMD6zOuKh|ryP Mln3NlU3ODNzMkK=
DU145 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnsPWVlUUN3ME2yMlI5yqEEsdMgNE4xPMLizszN MVGyOVYxOzF{Mh?=
HCT15 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPl[ZVXUUN3ME2wMlgyyqEEsdMgNE4xOcLizszN MWOyOVYxOzF{Mh?=
T47D NXTWTmp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnGS5NKSzVyPUOuNVjDqMLzwrCwMlEyyqEQvF2= MXKyOVYxOzF{Mh?=
SMMC-7721 MU\GeY5kfGmxbjDBd5NigQ>? NVXUPWY4PDBizszN MXe0PEBp MWjEUXNQ MkG2bY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> M1jiTVI2PTR2M{[x
MDA-MB-231 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e1SFczyqCq M2TvXGlEPTB;MkGuNuKhyrIEoESuNuKh|ryP MWKyOVQ5PjJzOR?=
MCF-7 NXfKbotJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3NuKhcA>? MlvxTWM2OD1zMD65xsDDucLiMj6xxsDPxE1? M1nXWVI2PDh4MkG5
Jurkat MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS3NuKhcA>? M1nyV2lEPTB;MT6yxsDDucLiMT61xsDPxE1? NHmxNXEzPTR6NkKxPS=>
HeLa NWHW[pI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHpfmc4OsLiaB?= NYPxcYdkUUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= NIG1VWYzPTR6NkKxPS=>
MCF7  M3\PcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrD[mQ2NTFyMDFOwG0> NHL0U|M4KGR? NWTObZhJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHz2RoMzPTR5Mk[xPS=>
K562 NGW2VZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILkelM4OsLiaB?= M{XTOWlEPTB;MD6yPeKh|ryP NWLGZnk3OjV{OEK2OVM>
K/VP.5 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi3NuKhcA>? NFrRRZpKSzVyPUSuPeKh|ryP NECzbHkzPTJ6Mk[1Ny=>
SH-EP  M1ThNmZ2dmO2aX;uJGF{e2G7 MlvNNlDDqM7:Zz;tcC=> M3T4UlI1yqCq M1yxSIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= MnvoNlUzPjF7OEG=
SCC25 M1ixUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXriUoxxOjUEoHi= M1TmSmlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= Ml\rNlUzOjB5Mkm=
CAL27 NEPHTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nWUlI1yqCq NGLmOIZKSzVyPUWyMlHDqMLzwrCxMlA6yqEQvF2= NX7QToNQOjV{MkC3Nlk>
FaDu M3LCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKyd2xLOjUEoHi= MlWzTWM2OD1{NT64PeKhyrIEoEGuNVPDqM7:TR?= NG[2TIczPTJ{MEeyPS=>
SCC25 NV7pN41MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PBUlQ5yqCq M1XPTWlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= MX:yOVIzODd{OR?=
CAL27 M{LITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPMc|M1QMLiaB?= MlLITWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= MUeyOVIzODd{OR?=
FaDu Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe0POKhcA>? MmHrTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP NGfqZY8zPTJ{MEeyPS=>
SCC25 NX7y[4dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFizTJQ4OsLiaB?= M33BcGlEPTB;OD60NeKhyrIEoEGuNVHDqM7:TR?= MlewNlUzOjB5Mkm=
CAL27 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTnO|LDqGh? MXjJR|UxRTRwMkhCpOKyyqBzLkG0xsDPxE1? NX3JZWloOjV{MkC3Nlk>
FaDu MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PZbFczyqCq M{frZ2lEPTB;NT6wNuKhyrIEoEGuNVXDqM7:TR?= NUCyPIJ2OjV{MkC3Nlk>
MCF-7 NHL3TI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPTcm41QMLiaNMg MoDTSG1UVw>? MkDKTWM2OD15LkNCpOKyyqByLklCpO69VQ>? M3rIdVI2OjF4M{e4
T-47D NYfK[FB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi3OHJNPDkEoHlCpC=> M1T6eGROW09? Ml;pTWM2OD15LkhCpOKyyqByLkhCpO69VQ>? M4nKV|I2OjF4M{e4
MDA-MB-231 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXeyW5NnPDkEoHlCpC=> MljnSG1UVw>? NUP1fFFHUUN3ME2xNk45yqEEsdMgNU4xyqEQvF2= NGTxflMzPTJzNkO3PC=>
DU145 NIO3OnBCeG:ydH;zbZMhSXO|YYm= Mn\5NVAuOTByIN88US=> NXLGZ2M6QCCq MmGwSG1UVw>? MmHUbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w Ml\QNlUyPDl4OEG=
DU145 stem-like NYqybGJGSXCxcITvd4l{KEG|c3H5 MlLoNVAuOTByIN88US=> MmPzPEBp NWXCO2NyTE2VTx?= NUfESXZ2cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlrYNlUyPDl4OEG=
DU145 NIfjeVBHfW6ldHnvckBCe3OjeR?= NID0THIyOC1zMECg{txO MVGyJIg> NV7JbndCTE2VTx?= M1rmeolv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmrQNlUyPDl4OEG=
DU145 stem-like MWTGeY5kfGmxbjDBd5NigQ>? MlvPNVAuOTByIN88US=> M{nBVVIhcA>? MkLoSG1UVw>? NVT6Vo5qcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVyyOVE1QTZ6MR?=
UW228-3 M1jpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPsSJdDOC5yMT2zNFAh|ryP M4XpV|Q5KGh? NFG2[|RFVVOR NITYOFVKSzVyPUCuPVnDqM7:TR?= NYL1R2o6OjVzMUmxPFU>
NSCs M{fHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rHW|AvODFvM{CwJO69VQ>? NEfwRZE1QCCq MW\EUXNQ MUnJR|UxRTBwMz2zxsDPxE1? NIHERXIzPTFzOUG4OS=>
MKL-1  NGrvcohHfW6ldHnvckBCe3OjeR?= M{Pld|ExNTFyMECgcm0> MlrwOEBl MW\pcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? M3y2SFI2OTF4N{W0
MCF7 EV NIHEOZlHfW6ldHnvckBCe3OjeR?= M4nlOVExNTFyMDFOwG0> MYqy5qCKcA>? NV7mNVN{cW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? M3S5OFI2ODh6MkCz
MCF 7BMI1 NFL4dJJHfW6ldHnvckBCe3OjeR?= NHvrdpEyOC1zMECg{txO MmXnNwKBkWh? NXi5dldUcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NEfNTFQzPTB6OEKwNy=>
MCF7 EV MmjwSpVv[3Srb36gRZN{[Xl? MWixNE0yODBizszN NX7zbZFLOuLCiXi= NVTQOG9PTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v MYmyOVA5QDJyMx?=
MCF7 BMI1 MW\GeY5kfGmxbjDBd5NigQ>? MoTENVAuOTByIN88US=> MUGy5qCKcA>? MYjFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= MYmyOVA5QDJyMx?=
HepG2 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjaTWVKTE2VT9Mg NFvneHJKSzVyPUOwMlE3yqEEsdMgNE42OMLizszN NW\KS2RqOjVyN{izNVE>
MOLT-3 NIexXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXQSG1UV8Li NYLFeldCUUN3ME2wMlA2OcLiwsJCpFAvODB{wrFOwG0> MnTDNlUxPzh|MUG=
HT1080 NXzGNmk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCxMVExOCEQvF2= M1K5OVQwOjRxNEigbC=> MWjEUXNQyqB? NUnySYY5cW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u M3fkW|I2ODd6ME[0
HT1080 NInycnVHfW6ldHnvckBCe3OjeR?= M3W5VlAvODByMT2xNFAh|ryP NIr5UogyNTJ2IHi= Mn;JSG1UV8Li NIfCXW5qdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= M4XDdlI2ODd6ME[0
HT1080 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL0NE4xODBzLUGwNEDPxE1? MXKyOEBp M4XGSmROW00EoB?= NFLscHNk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz MkXrNlUxPzhyNkS=
HD-MY-Z MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDyXmUyOjRxNEivO|IhcA>? NYjPRndJUUN3MP-8olExOCEQvF2= MXmyOVA1QDJ|Nh?=
DOHH-2 NETqbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXiyOEBp MVPJR|Ux97zgMUCwJO69VQ>? MnGxNlUxPDh{M{[=
DOHH-2 M2XVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX0O201QCCq NGHONoJKSzVyPUG5MlnDqM7:TR?= NFv2SpIzPTB2OEKzOi=>
DOHH-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHXfWlZPzJiaB?= M{fyTWlEPTB;NdMg{txO NGLHOGEzPTB2OEKzOi=>
REH NFnVNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOzT4QzPCCq MkflTWM2OD1yLkCyO:Kh|ryP MnmwNlUxPDh{M{[=
REH NVfqToF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVS0PEBp MYTJR|UxRTBwMEG0xsDPxE1? NGjKb4MzPTB2OEKzOi=>
REH Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3CNJA4OiCq M1zDVmlEPTB;MD6wNVXDqM7:TR?= NYfEO5F4OjVyNEiyN|Y>
HH M{X3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7hNGUzPCCq NWfCTld[UUN3ME2xNFQvP8LizszN NWjpU4J3OjVyNEiyN|Y>
HH NIjhOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS0PEBp NXHsRmFKUUN3ME20PE43yqEQvF2= MlnrNlUxPDh{M{[=
HH NWnCd4NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmewO|IhcA>? MmP3TWM2OD1zND63xsDPxE1? M4TVV|I2ODR6MkO2
HuT-78 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzRNlQhcA>? NXzqXW9QUUN3ME25MlPDqM7:TR?= M3i5R|I2ODR6MkO2
HuT-78 M2DXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;j[ms1QCCq M3rZfWlEPTB;ND6zxsDPxE1? MYeyOVA1QDJ|Nh?=
HuT-78 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37k[FczKGh? MY\JR|UxRTRwMtMg{txO MUeyOVA1QDJ|Nh?=
OPM-2 M2[xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiyOEBp NW\HNoNDUUN3ME2yOE4yyqEQvF2= NHvNfnczPTB2OEKzOi=>
OPM-2 M1LpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnpRmg{PDhiaB?= MWHJR|UxRTUEoN88US=> MVKyOVA1QDJ|Nh?=
OPM-2 NE[2R4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH1RZlFPzJiaB?= MYjJR|UxRTFwM9Mg{txO NEDFNIozPTB2OEKzOi=>
RPMI-8226 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmyOEBp NIn3VYtKSzVyPUGwOk43yqEQvF2= NW\scJplOjVyNEiyN|Y>
RPMI-8226 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO2OFghcA>? NHW4[2lKSzVyPUmxMlHDqM7:TR?= Mn[4NlUxPDh{M{[=
RPMI-8226 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3KfoFVPzJiaB?= NIOxOYdKSzVyPUG0MlnDqM7:TR?= M{LFdFI2ODR6MkO2
U-266 NX3QTolFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n2bFI1KGh? NG\iOYdKSzVyPUi2MlLDqM7:TR?= NI\3UXAzPTB2OEKzOi=>
U-266 NHvh[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPHPGlPPDhiaB?= NXzxOWxxUUN3ME22PE41yqEQvF2= NHO1U5UzPTB2OEKzOi=>
U-266 M2XYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXsV3JpPzJiaB?= NELGdY1KSzVyPUK3MlTDqM7:TR?= NXzRV453OjVyNEiyN|Y>
Kelly NVH6WmJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTLfGQxNTFyIN88US=> MYe3NuKhcA>? NFi1[45KSzVyPUGuOVE5yqEQvF2= MnHpNlUxODh7MEC=
SH-SY5Y  NGG3dYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorqNE0yOCEQvF2= NHzES5c4OsLiaB?= MWrJR|UxRTBwN{W0xsDPxE4EoB?= Mme0NlUxODh7MEC=
SK-N-AS NHTF[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\OTo8xNTFyIN88US=> M2HHRlczyqCq NGXvXYlKSzVyPUGuO|EzyqEQvF5CpC=> MmHMNlUxODh7MEC=
SK-N-DZ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjyeZcxNTFyIN88US=> MYq3NuKhcA>? M1jkR2lEPTB;NT60PFXDqM7:TR?= NX25TnQzOjVyMEi5NFA>
HepG2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrvclUxPDkEoHi= MUnEUXNQyqB? M2HSZ2lEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= MXKyOFk6PjF|Nh?=
A549 NF;pSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzUOFjDqGh? NH;J[HBFVVORwrC= M1XWZWlEPTB;MkSxMlnDqMLzwrCzNU4zO8LizszN M4\vc|I1QTl4MUO2
MCF7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\BZ|ZRPDkEoHi= NWrHOXhtTE2VT9Mg MnXBTWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= NGfaSm4zPDl7NkGzOi=>
HL-60  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LrPVczyqCq NYrjO2lzUUN3ME2wMlEz6oDHzszN NUHGVXhUOjR7OUOwNVQ>
HL-60[R] Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPE[W84OsLiaB?= MVfJR|UxRTNwMUNihKXPxE1? NEHyZY4zPDl7M{CxOC=>
MIAPACA MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X0e2dKPTB;MT6zJOKyKDBwMEOg{txO NWT4boU4OjR7NUO4NlE>
MCF-7 M4C1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HrbWdKPTB;MD6yOUDDuSByLkGg{txO MV2yOFk2Ozh{MR?=
HeLa M3\C[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XPXGdKPTB;MD62OEDDuSByLkSg{txO M3TiU|I1QTV|OEKx
MO59K  NFzuWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7HO{Bl Mon4TWM2OD1yLkG35qCG|ryP M1z1cVI1QTV|NU[x
MO59J MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofZO{Bl M2XUOWlEPTB;MD6x5qCG|ryP NIHScIwzPDl3M{W2NS=>
ME 180 M1;adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPkd3c1QMLiaNMg M4TuZWlEPTB;OD65xsDDucLiMD6z5qCG|ryP NGGxPIkzPDl3M{CyOy=>
MCF-7 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[0POKhcMLi MUHJR|UxRTJ|LkmgxtEhOC5|4pEF{txO NWPRRXpOOjR7NUOwNlc>
HeLa NEG2XWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jBWVQ5yqCqwrC= NGLqcmJKSzVyPUSuO|EhyrFiMT605qCG|ryP MkXaNlQ6PTNyMke=
MDA-MB-453 NET4XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO0POKhcMLi MXLJR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? MXiyOFk2OzB{Nx?=
MDA-MB-231 NWjydHBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fDeVQ5yqCqwrC= NYnybYdDUUN3ME2yOE4zOiEEsTCyMlk16oDHzszN MljXNlQ6PTNyMke=
PC-3 M2m0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjJXXA1QMLiaNMg MXHJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? MmPtNlQ6PTNyMke=
HT-29 NXrCUVd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW0POKhcMLi MkH2TWM2OD1{MT60OUDDuSB|Lki35qCG|ryP MXmyOFk2OzB{Nx?=
BGC-823 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG0POKhcMLi NGPO[YVKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= M4i4RVI1Pzl|OEe3
HeLa MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL2cnJkPDkEoHlCpC=> MWrJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= NIW5TYozPDd7M{i3Oy=>
A549 NVf5U5htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjvSW41QMLiaNMg M4j0W2lEPTB;MUO5MlU1KMLzIEeuNFXjiIYQvF2= M4nUdVI1Pzl|OEe3
HK-2 NHP3V5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zOFjDqGkEoB?= NUPpe2pmUUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= NXzCOlhxOjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
- 合并

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
- 合并
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Formulation: 生理盐水
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
储存条件 粉状
溶于溶剂
别名 VP-16, VP-16213

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03264131 Recruiting Drug: Brentuximab Vedotin|Drug: CHEP Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. October 15 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID